Freire Beatriz Marton, de Melo Filipe Menegatti, Basso Alexandre S
Departamento de Microbiologia, Imunologia e Parasitologia, Escola Paulista de Medicina, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Immunother Adv. 2022 Jun 1;2(1):ltac010. doi: 10.1093/immadv/ltac010. eCollection 2022.
Macrophages are immune cells that are widespread throughout the body and critical for maintaining tissue homeostasis. Their remarkable plasticity allows them to acquire different phenotypes, becoming able either to fight infection (M1-like, classically activated macrophages) or to promote tissue remodeling and repair (M2-like, alternatively activated macrophages). These phenotypes are induced by different cues present in the microenvironment. Among the factors that might regulate macrophage activation are mediators produced by different branches of the nervous system. The regulation exerted by the sympathetic nervous system (SNS) on macrophages (and the immune system in general) is becoming a subject of increasing interest, indeed a great number of articles have been published lately. Catecholamines (noradrenaline and adrenaline) activate α and β adrenergic receptors expressed by macrophages and shape the effector functions of these cells in contexts as diverse as the small intestine, the lung, or the adipose tissue. Activation of different subsets of receptors seems to produce antagonistic effects, with α adrenergic receptors generally associated with pro-inflammatory functions and β adrenergic receptors (particularly β2) related to the resolution of inflammation and tissue remodeling. However, exceptions to this paradigm have been reported, and the factors contributing to these apparently contradictory observations are still far from being completely understood. Additionally, macrophages seem to be sources of catecholamines, which is also a subject of some debate. In this review, we discuss how activation of adrenergic receptors modulates macrophage effector functions and its implications for inflammatory responses and tissue homeostasis.
Immunother Adv. 2022-6-1
Crit Rev Eukaryot Gene Expr. 2016
Front Immunol. 2021
Curr Res Immunol. 2021-11-25
MedComm (2020). 2024-8-1
Ann Endocrinol (Paris). 2021-6
Endocr Metab Immune Disord Drug Targets. 2019
J Cell Physiol. 2018-3-1
Brain Behav Immun. 2019-6-5
Front Neurol. 2025-7-25
Int J Mol Sci. 2025-7-16
Am J Physiol Endocrinol Metab. 2025-8-1
J Neuroimmune Pharmacol. 2025-5-30
Results Probl Cell Differ. 2024
J Mol Cell Cardiol. 2024-11
Cell Signal. 2021-4
Cell. 2020-7-23
Cancer Prev Res (Phila). 2020-9